Our Science

Developing novel treatments for CNS conditions

Throughout our history, Saadia Pharmaceuticals has built a robust research and development program.

We apply method patent strategies to develop impactful treatments that are designed to improve the lives of patients with CNS conditions.

This dedication to research has resulted in a successful track record of developing novel pipeline products.

The science that drives

The science that drives our pipeline products

our pipeline products

Research and development are what we do at Saadia Pharmaceuticals
Explore the science behind our work and pipeline of impactful product candidates

Autism Spectrum Disorder

Autism Spectrum Disorder (ASD) is often a life-long condition affecting millions of children and adults worldwide and is associated with exorbitant costs for special education, therapies, and long-term care.

Saadia Pharmaceuticals developed a patented combination pharmacotherapy comprised of FDA-safe ingredients that addresses both the core symptoms of ASD (social-emotional reciprocity, restricted areas of interest/repetitive behaviors) and associated symptoms of impulsivity, hyperactivity, irritability, and constipation.

The combination has demonstrated safety and efficacy in over 500 patients for the past 10 years.

Treatment-Resistant Depression

Treatment-Resistant Depression (TRD) in adults, defined as a failure of at least 2 oral antidepressants of adequate dose and duration in the current episode, is a ubiquitous condition with a poor prognosis.

The World Health Organization recognizes Depression as the leading cause of disability. Saadia Pharmaceuticals patented a novel use of an FDA-approved compound that has demonstrated safety and efficacy for Depression over the past 2 decades.

Harmful Algal Blooms

Harmful Algal Blooms (HAB) have recently overgrown vast numbers of bodies of water due to climate change.

HAB have demonstrated toxicity in humans with the potential to go airborne.

Current mitigation strategies have focused on closing beaches. Saadia Pharmaceuticals patented a novel use of a naturally occurring compound that destroys HAB without posing toxicity to the environment or to its inhabitants.

A.I. Psychiatry

A.I. Psychiatry (AI Ѱ™) is a proprietary machine learning algorithmic technology pioneered by Saadia Pharmaceuticals to address the worldwide shortage of experienced psychiatrists. Neuropsychiatric illness is now the leading cause of mortality and morbidity worldwide. There will never be a sufficient supply of psychiatrists to meet the growing demand.


Online patient-directed interventions, Physician Assistants, Nurse Practitioners, and General Practitioners are trying to fill the void but would greatly benefit from AI Ѱ™ as an expert virtual consultant to assist patients and practitioners with diagnosis, prognosis, and treatment decisions.

Discover how we’re turning ideas into
innovations that can transform lives

Our Pipeline

Explore our innovative product candidates

Our Team

Meet the dedicated team behind our healthcare solutions